Patent Application
20180273986
The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 313632019910SeqList.txt, date recorded: Dec. 13, 2017, size: 284,896 KB).
The invention relates to the field of microbial production, more specifically production of organic acids, such as citric acid and its derivatives, such as oxaloacetic acid, itaconic acid (itaconate) and metacrylic acid, more specifically the production thereof in micro-organisms.
One of the most fundamental and ubiquitous metabolic pathways in living organisms is the citric acid cycle, or Krebs cycle, named after the discoverer. In eukaryotes this process takes place in the mitochondrion and is fed mainly by pyruvate and acetyl-CoA that are transported from the cytoplasm into the mitochondrion. Some of the constituents of the Krebs cycle or derivatives thereof may be transported back to the cytoplasm by active transport mechanisms, in general by tricarboxylic acid transporters. This basically means that cytoplasmatic metabolic routes that are dependent on, or starting from organic acids such as citric acid (citrate), malic acid (malate) oxaloacetic acid (oxaloacetate) heavily depend, and in general are limited by the activity within the Krebs cycle and the availability of the tricarboxylic acid transporters.
Hitherto no specific metabolic route for the production of extramitochondrial citric acid was elucidated. Yet, the availability of citric acid in the cytoplasm is extremely useful for the production of this acid itself and, even more importantly, for the production of derivatives and metabolites of citric acid. Citric acid is the starting point for many metabolic routes. One important metabolic route is the production of itaconic acid.
Production and metabolism of itaconic acid in microbial cells has been studied extensively for several decades (Calam, C. T. et al., 1939, Thom. J. Biochem., 33:1488-1495; Bentley, R. and Thiessen, C. P., 1956, J. Biol. Chem. 226:673-720; Cooper, R. A. and Kornberg, H. L., 1964, Biochem. J., 91:82-91; Bonnarme, P. et al., 1995, J. Bacteriol. 117:3573-3578; Dwiarti, L. et al., 2002, J. Biosci. Bioeng. 1:29-33), but the metabolic pathway for itaconic acid has not been unequivocally established (Wilke, Th. and Vorlop, K.-D., 2001, Appl. Microbiol. Biotechnol. 56:289-295; Bonnarme, P. et al., 1995, J. Bacteriol. 177:3573-3578). Two complicating factors in this respect are that the biosynthesis route for itaconic acid is thought to occur both in the cytosol and the mitochondria (Jaklitsch, W. M. et al., 1991, J. Gen. Microbiol. Appl. 6:51-61) and that aconitase, the enzyme that interconverts citric acid into cis-aconitate, and vice versa, and other enzymes in the metabolic pathway have been found to be present in many isoforms in microbial cells.
The general scheme currently envisioned for itaconic acid biosynthesis is given in
The production of itaconic acid from citrate has been achieved in Aspergillus (and also other micro-organisms) with technology as described in WO 2009/014437, WO 2009/104958 and WO 2009/110796.
However, next to itaconate, citrate can also be used as a starting point for the production of malate, succinate, glutamate and metacrylic acid.
Further, citric acid can also lead to a metabolic route for lysine and from there to penicillin and similar compounds. Alternatively, citric acid can lead to the synthesis of fatty acids and thus be a source for biodiesel production. Moreover metabolites of citric acid, in particular acetyl-CoA, form the basis of biosynthetic routes towards fatty acids, polyketides and the mevalonate pathway towards terpenoids and other compounds
Yet, however, there is still need for an enzyme capable of production or overproduction of citric acid.
The present inventors now have elucidated a gene coding for an enzyme that is able to catalyze the reaction from oxaloacetate to citric acid, a so-called citrate synthase enzyme, which is present and functional outside the mitochondrion (and probably in the cytoplasm) of eukaryotic organisms.
The invention therefore comprises the use of a protein having cytosolic citric acid synthase activity for the heterologous production of citrate in the cytosol of a micro-organism or algae, preferably wherein said micro-organism is a fungus or a yeast or a plant or algal cell, more preferably when said micro-organism is selected from the group of Aspergillus spp., more particularly, A. niger, A. nidulans, A. terreus, A. clavatus, A. oryzae or A. flavus, Neurospora spp., more particularly N. crassa or N. tetrasperma, Sclerotina, Gibberella, Coniothyrium, Psiticum, Magnaporthe, Podospora, Chaetomium, Phaeosphaeria, Botryotinia, Neosartorya, Pyrenophora, Panicum, Aureococcus, Penicillium, Trichoderma, Sordaria, Colleotrichum, Verticillium, Arthrobotrys, Nectria, Leptosphaeria, Fusarium, Glomerella, Geomyces, Myceliophthora, Pichia, Saccharomyces spp., such as S. pastorianus, S. cerevisiae, S. boulardii, S. carlsbergensis, S. kudriavzevii, and S. paradoxus, Zygosaccharomyces, Schizosaccharomyces pombe, Kluyveromyces spp., Yarrowia lipolytica, Monascus spp. (such as M. rubber, M. purpureus, M. pilosus, M. vitreus and M. pubigerus), Penicillium spp. (such as P. citrinum, P. chrysogenum), Hansenula spp., Torulaspora delbrueckii, Hypomyces spp., Dotatomyces spp. (such as D. stemonitis), Issatchenko orientalis, Phoma spp., Eupenicillium spp., Gymnoascus spp., Pichia labacensis, Pichia anomala, Wickerhamomyces anomalus, Candida cariosilognicola, Paecilomyces virioti, Scopulariopsis brevicaulis, Brettanomyces spp., such as B. bruxellensis, B. anomalus, B. custersianus, B. naardenensis and Brettanomyces nanus, Dekkera bruxellensis, Dekkera anoma and Trichoderma spp. (such as T. viride).
Preferably in said use the protein is derived from A. niger. It is also preferred when the protein is A. niger An08g10920 or an ortholog thereof, more particularly, wherein such an ortholog is chosen from the group of CAK45764.1/An08g10920, XP001393195.2/ANTI1_1474074, EHA18674.1/Aspni5_176409, NP_001142237.1, GAA88109.1/ AKAW_06223, EIT75413.1/Ao3042_08560, XP_001827205.1/AOR_1_298024, AO090010000170, XP_002384448.1/AFLA_117410, AFL2G_11427, XP_002148678.1/PMAA_091390, Aspfo1_0085419, Acar5010_212258, Acar5010_171837, Aspbr1_0068777, Asptu1_0164827, and proteins having a percentage identity of 70%, more preferably 75%, more preferably 80%, more preferably 85%, more preferably 90%, more preferably 95%, more preferably 98%, more preferably 99% with An08g10920.
Further part of the invention is a vector for transforming a micro-organism comprising a nucleic acid sequence coding for a protein as defined above. Also part of the invention is a transgenic organism transformed with such a vector or comprising a heterologous citric acid synthase as defined above.
The invention also comprises a method for the production of citric acid comprising overexpression of a gene coding for a citric acid synthase as defined above.
In a further preferred embodiment, the invention comprises a method for the production of itaconic acid comprising overexpression of a gene coding for a citric acid synthase as defined above and overexpression of a gene coding for the enzyme cis-aconitic acid decarboxylase (CAD) in a suitable host cell.
In an also preferred embodiment of the present invention, the invention also comprises a method for the production of a derivative of citric acid comprising overexpression of a gene coding for a citric acid synthase as defined in any of claim 1, 2 or 3 and overexpression of one or more genes that encode enzymes that are capable of converting citric acid into said derivative of citric acid in a suitable host cell. Preferably in such a method said one or more genes are selected from the group comprising An08g10860 (fatty acid synthase subunit beta), An08g10870 (2-methylcitrate dehydratase, prpD) ( ); An08g10880 (GAL4; GAL4-like Zn2Cys6 binuclear), An08g10930 (3-oxoacyl-[acyl-carrier-protein] synthase); An08g10970 (MFS multidrug transporter); An08g10980 (transcription factor acetate regulatory DNA binding protein facB), An01g09950, An09g06220, An15g01780, An02g14730 (cytosolic prpD family)', An05g02230 and An08g10530 (cytosolic aconitases) An02g12430, (non-mitochondrial isocitrate dehydrogenase) An04g06210 (homocitrate synthase), Anl1g00510 and An11g00530 (citrate lyase). Further preferred in such a method said suitable host cell is a micro-organism or algae, more preferably a fungus or a yeast or a plant or algal cell, preferably selected from the group of Aspergillus spp., more particularly, A. niger, A. nidulans, A. terreus, A. clavatus, A. oryzae or A. flavus, Neurospora spp., more particularly N. crassa or N. tetrasperma, Sclerotina, Gibberella, Coniothyrium, Psiticum, Magnaporthe, Podospora, Chaetomium, Phaeosphaeria, Botryotinia, Neosartorya, Pyrenophora, Panicum, Aureococcus, Penicillium, Trichoderma, Sordaria, Colleotrichum, Verticillium, Arthrobotrys, Nectria, Leptosphaeria, Fusarium, Glomerella, Geomyces, Myceliophthora, Pichia, Saccharomyces spp., such as S. pastorianus, S. cerevisiae, S. boulardii, S. carlsbergensis, S. kudriavzevii, and S. paradoxus, Zygosaccharomyces, Schizosaccharomyces pombe, Kluyveromyces spp., Yarrowia lipolytica, Monascus spp. (such as M. rubber, M. purpureus, M. pilosus, M. vitreus and M. pubigerus), Penicillium spp. (such as P. citrinum, P. chrysogenum), Hansenula spp., Torulaspora delbrueckii, Hypomyces spp., Dotatomyces spp. (such as D. stemonitis), Issatchenko orientalis, Phoma spp., Eupenicillium spp., Gymnoascus spp., Pichia labacensis, Pichia anomala, Wickerhamomyces anomalus, Candida cariosilognicola, Paecilomyces virioti, Scopulariopsis brevicaulis, Brettanomyces spp., such as B. bruxellensis, B. anomalus, B. custersianus, B. naardenensis and Brettanomyces nanus, Dekkera bruxellensis, Dekkera anoma and Trichoderma spp. (such as T. viride), most preferably wherein said micro-organism is chosen from the group consisting of Aspergillus niger, A.acidus, A.tubigensis, A. oryzae, A. kawachii, A. flavus, A. acidus, A. carbonarius, A. brasiliensis, S.cerevisiae, Talaromyces marneffei, Zea mays, Pichia anomala and Dekkera bruxellensis.
The invention als comprises a method for the production of a derivative of citric acid, preferably wherein said derivative is itaconic acid comprising overexpression of a gene coding for a citric acid synthase as defined in any of claim 1, 2 or 3 and a gene encoding for protein that is involved in the production or transport of itaconate or any precursor thereof, preferably wherein the gene is selected from the group of cis-aconitic acid decarboxylase (CAD), ATEG_09969.1, ATEG_09970.1 and ATEG_09972.1.
In a further preferred embodiment the invention comprises a method as defined above, wherein said host cell is cultured under anaerobic conditions. Alternatively or additionally, the invention comprises a method as defined above, wherein said host cell is cultured under anaerobic conditions in the presence of nitrate as N-source.
“Fungi” are herein defined as eukaryotic microorganisms and include all species of the subdivision Eumycotina (Alexopoulos, C. J., 1962, In: Introductory Mycology, John Wiley & Sons, Inc., New York). The term fungus thus includes both filamentous fungi and yeast. “Filamentous fungi” are herein defined as eukaryotic microorganisms that include all filamentous forms of the subdivision Eumycotina. These fungi are characterized by a vegetative mycelium composed of chitin, cellulose, and other complex polysaccharides. The filamentous fungi used in the present invention are morphologically, physiologically, and genetically distinct from yeasts. Vegetative growth by filamentous fungi is by hyphal elongation and carbon catabolism of most filamentous fungi are obligately aerobic. “Yeasts” are herein defined as eukaryotic microorganisms and include all species of the subdivision Eumycotina that predominantly grow in unicellular form. Yeasts may either grow by budding of a unicellular thallus or may grow by fission of the organism.
The term “fungal”, when referring to a protein or nucleic acid molecule thus means a protein or nucleic acid whose amino acid or nucleotide sequence, respectively, naturally occurs in a fungus.
The core of the invention resides in the discovery of a new, alternative parallel pathway for the production of citric acid from oxaloacetic acid. Most surprisingly, said production takes place outside of the mitochondrion, and probably in the cytoplasm. Accordingly, this route is active even under conditions where the mitochondrial citric acid cycle is inactive, which means that production of citric acid can advantageously take place in the absence of an active TCA cycle under anaerobic or low oxygen conditions. Further, it has appeared that the enzyme is expressed during the stationary phase, which means that an overexpression of citric acid can be achieved without any biomass growth of the producing organism. Moreover, previous research (Rafledge C., 2000, FEMS Microbiol. Lett. 189(2):317-319; Ruijter G. et al., 2000, FEMS Microbiol. Lett. 184(1): 35-40; Murray, S. and Hynes, M. 2010, Eukaryotic Cell 9(4):656-666) has shown that improvement of product fluxes through rational manipulation of the central metabolism (citrate synthase) has not been successful, which is in contrast to the results obtained in the present invention
For sake of easy reference, the enzyme will be addressed in this specification as the citrate synthase B or citB-enzyme, or just citB.
The citB gene as originally isolated was derived from Aspergillus niger. However, also comprised in the invention are homologous proteins that are derived from other micro-organisms (also called orthologs) and the nucleotide sequences coding for these. It will be clear for a person skilled in the art that on basis of the nucleotide sequences coding for the CitB enzyme of A. niger orthologs from other micro-organism species can be easily found through database searching in the NCBI GenBank based on sequence similarity and alignment analysis using minimal gap size in the alignment. A list of these orthologs is presented in Table 1a.
Table 1a List of citB orthologs found in the NCBI GenBank database and orthologous genes in Aspergillus species (AspGD database, Broad institute). The sequences of these genes are given in
Also part of the invention are nucleotide sequences which are conservatively modified variants of the above mentioned sequences or polymorphic variants thereof. Those of skill in the art will recognize that the degeneracy of the genetic code allows for a plurality of polynucleotides to encode the identical amino acid. Such “silent variations” can be used, for example, to selectively hybridize and detect allelic variants of the nucleotide sequences of the present invention. Additionally, the present invention provides isolated nucleotide sequences comprising one or more polymorphic (allelic) variants of the above nucleotide sequences. Further part of the invention are polynucleotides still coding for a protein which has a biological function identical to the function of the CitB enzyme, which are the product of amplification from a nucleotide library using primer pairs which selectively hybridize under stringent conditions to loci within the above mentioned nucleotide sequences. The primer length in nucleotides is selected from the group of integers consisting of from at least 15 to 50. Those of skill in the art will recognize that a lengthened primer sequence can be employed to increase specificity of binding (i.e. annealing) to a target sequence. Stringent conditions in this respect means a reaction at a temperature of between 60° C. and 65° C. in 0.3 strength citrate buffered saline containing 0.1% SDS followed by rinsing at the same temperature with 0.3 strength citrate buffered saline containing 0.1% SDS.
Thus, also part of the invention are polynucleotides which selectively hybridize, under selective hybridization conditions, to one or more of the above discussed nucleotide sequences, and which code for an amino acid sequence which has a biological function similar to the function of the CitB enzyme disclosed in the present invention. With “a biological function similar to the function of CitB” it is meant the ability to convert oxaloacetate into citrate and to perform this conversion outside the mitochondrion, in the cytoplasm.
Another way to indicate hybridization potential is on sequence identity. In this sense, the present invention provides also for nucleotide sequences which have a percentage of identity related to the above mentioned sequences of 65% to 95%. Thus, for example, the percentage of identity can be at least, 65%, 70%, 75%, 80%, 85%, 90%, or 95%. Sequence identity on nucleotide sequences can be calculated by using the BLASTN computer program (which is publicly available, for instance through the National Center for Biotechnological Information, accessible via the interne on http://www.ncbi.nlm.nih.gov/) using the default settings of 11 for wordlength (W), 10 for expectation (E), 5 as reward score for a pair of matching residues (M), −4 as penalty score for mismatches (N) and a cutoff of 100.
Similarly, the homology can be calculated on basis of the amino acid sequence of the enzyme encoded by said nucleotide sequences. For amino acids, the sequence identity can be calculated through the BLASTP computer program (also available through http://www.ncbi.nlm.nih.gov/). On the amino acid level homologues or orthologs are defined as amino acid sequences having a biological function similar to the CitB enzyme and having a sequence identity of at least 50%, preferably at least 55%, preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, more preferably at least 95% to the amino acid sequence of the A. niger CitB enzyme as depicted in
Further included in the invention are enzymes, and nucleotide sequences coding for such enzymes, with a functional citrate synthase activity, but which lack the signal sequence that normally would cause them to be expressed or to be functional in the mitochondrion. Further included in the present invention and within the definition of citB according to the invention are mitochondrial citrate synthase enzymes in which the signal sequence has been replaced with the signal sequences of the A. niger citB enzyme (An08g10920).
As is shown in the Examples, also the enzymes with annotation An01g09940 and An09g03570 lack the mitochondrial signal protein part. It is thus envisaged that these proteins and orthologs of these proteins would also qualify as citB enzymes according to the invention. These enzymes and their orthologs, listed in the Table 1b below, are also depicted in
fischeri NRRL 181]
digitatum Pd1]
All of these proteins, and orthologs and homologs as defined, are deemed to be encompassed in the term “citB protein” or “citB enzyme” as used herein.
It is further contemplated that overexpression of the gene in a heterologous organism, which in nature does not or hardly produce extramitochondrial citric acid, is able to provide such an organism with a functional pathway for expression of citric acid outside the mitochondrion, and preferably in the cytoplasm. Preferably such overexpression is accomplished in filamentous fungi, yeasts and/or bacteria, such as, but not limited to, Aspergillus sp., such as the fungi A. terreus, A. itaconicus, A. oryzae and A niger, Ustilago zeae, Ustilago maydis, Ustilago sp., Candida sp., Mortierella sp., Yarrowia sp., Rgizopus sp. Yarrowia lipolytica, Rhodotorula sp. and Pseudozyma Antarctica, the bacterium E.coli and the yeast Saccharomyces sp, e.g. S. cerevisiae, Pichia sp, e.g. P. pastoris or P. anomala. Also plant cells and algal cells and cell cultures may be used as host. Especially preferred are heterologous organisms in which the substrate oxaloacetate is abundantly available in the host organism. Also applicable in the present invention are hosts that may grow anaerobically while using NO3 als source of nitrogen, such as the yeasts P. anomala and Dekkera bruxellensis. In such a case the acceptor nitrate can yield reductive compounds in the same was as oxygen produces reductive compounds in aerobic fermentation. Similarly also Aspergillus species, such as A. terreus can grow at very low oxygen levels using dissimilatory nitrate reduction (Stief, P., Fuchs-Ocklenburg, S., Kamp, A., Manohar, C.-S., Houbraken, J., Boekhout, T., De Beer, D., Stoeck, T.Dissimilatory nitrate reduction by Aspergillus terreus isolated from the seasonal oxygen minimum zone in the Arabian Sea(2014) BMC Microbiology, 14 (1), art. no. 35) allowing the production of organic acids as described in the present invention under these conditions.
Further preferred are host organisms which next to the heterologous citB enzyme further contain enzymes that specifically metabolize citric acid further. One of the pathways which is very suitable for this is the pathway to form itaconic acid, wherein from citric acid cis-aconitate is formed by the enzyme aconitase or the enzyme (2-methyl)citrate dehydratase, which enzymes are considered to be functional in the cytosol (see
Accordingly, the combination of an heterologous citB gene and a gene selected from the group of di/tricarboxylate transporters is not only advantageous for the production of itaconate, but it may also cause an increase in the expression of other citrate derivatives as discussed above.
Of course, ideally, combinations of citB with one or more and preferably all of the genes that have been specified above as enhancing the production of itaconic acid maybe applied to act in concert to boost the production and transport of itaconic acid and/or its derivatives.
Recombinant host cells can be obtained using methods known in the art for providing cells with recombinant nucleic acids. These include transformation, transconjugation, transfection or electroporation of a host cell with a suitable plasmid (also referred to as vector) comprising the nucleic acid construct of interest operationally coupled to a promoter sequence to drive expression. Host cells of the invention are preferably transformed with a nucleic acid construct as further defined below and may comprise a single but preferably comprises multiple copies of the nucleic acid construct. The nucleic acid construct may be maintained episomally and thus comprise a sequence for autonomous replication, such as an ARS sequence. Suitable episomal nucleic acid constructs may e.g. be based on the yeast 2μ or pKD1 (Fleer et al., 1991, Biotechnology 9: 968-975) plasmids. Preferably, however, the nucleic acid construct is integrated in one or more copies into the genome of the host cell. Integration into the host cell's genome may occur at random by illegitimate recombination but preferably the nucleic acid construct is integrated into the host cell's genome by homologous recombination as is well known in the art of fungal molecular genetics (see e.g. WO 90/14423, EP-A-0 481 008, EP-A-0 635 574 and U.S. Pat. No. 6,265,186).
Transformation of host cells with the nucleic acid constructs of the invention and additional genetic modification of the fungal host cells of the invention as described above may be carried out by methods well known in the art. Such methods are e.g. known from standard handbooks, such as Sambrook and Russel (2001) “Molecular Cloning: A Laboratory Manual (3rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, or F. Ausubel et al, eds., “Current protocols in molecular biology”, Green Publishing and Wiley Interscience, New York (1987). Methods for transformation and genetic modification of fungal host cells are known from e.g. EP-A-0 635 574, WO 98/46772, WO 99/60102 and WO 00/37671.
In another aspect the invention relates to a nucleic acid construct comprising a nucleotide sequence encoding a CitB enzyme or homolog or ortholog thereof as defined above and used for transformation of a host cell as defined above. In the nucleic acid construct, the nucleotide sequence encoding the CitB protein preferably is operably linked to a promoter for control and initiation of transcription of the nucleotide sequence in a host cell as defined below. The promoter preferably is capable of causing sufficient expression of the CitB enzyme in the host cell. Promoters useful in the nucleic acid constructs of the invention include the promoter that in nature provides for expression of the CitB gene. Further, both constitutive and inducible natural promoters as well as engineered promoters can be used. Promoters suitable to drive expression of the CitB gene in the hosts of the invention include e.g. GALT, GAL10, or GAL 1, CYC1, HIS3, PGL, PH05, ADC1 , TRP1 , URA3, LEU2, ENO, TPI, and A0X1. Other suitable promoters include PDC, GPD1, PGK1, TEF, TDH, promoters from glycolytic genes (e.g. from a glyceraldehyde-3-phosphate dehydrogenase gene), ribosomal protein encoding gene promoters, alcohol dehydrogenase promoters (ADH1, ADH4, and the like), promoters from genes encoding amylo- or cellulolytic enzymes (glucoamylase, TAKA-amylase and cellobiohydrolase). Other promoters, both constitutive and inducible and enhancers or upstream activating sequences will be known to those of skill in the art. The promoters used in the nucleic acid constructs of the present invention may be modified, if desired, to affect their control characteristics. Preferably, the promoter used in the nucleic acid construct for expression of the CitB gene is homologous to the host cell in which the CitB protein is expressed.
In the nucleic acid construct, the 3′-end of the nucleotide acid sequence encoding the CitB enzyme preferably is operably linked to a transcription terminator sequence. Preferably the terminator sequence is operable in a host cell of choice. In any case the choice of the terminator is not critical; it may e.g. be from any fungal gene, although terminators may sometimes work if from a non-fungal, eukaryotic, gene. The transcription termination sequence further preferably comprises a polyadenylation signal.
Optionally, a selectable marker may be present in the nucleic acid construct. As used herein, the term “marker” refers to a gene encoding a trait or a phenotype which permits the selection of, or the screening for, a host cell containing the marker. A variety of selectable marker genes are available for use in the transformation of fungi. Suitable markers include auxotrophic marker genes involved in amino acid or nucleotide metabolism, such as e.g. genes encoding ornithine-transcarbamylases (argB), orotidine-5′-decaboxylases (pyrG, URA3) or glutamine-amido-transferase indoleglycerol-phosphate-synthase phosphoribosyl-anthranilate isomerases (trpC), or involved in carbon or nitrogen metabolism, such e.g. niaD or facA, and antibiotic resistance markers such as genes providing resistance against phleomycin, bleomycin or neomycin (G418). Preferably, bidirectional selection markers are used for which both a positive and a negative genetic selection is possible. Examples of such bidirectional markers are the pyrG (URA3), facA and amdS genes. Due to their bidirectionality these markers can be deleted from transformed filamentous fungus while leaving the introduced recombinant DNA molecule in place, in order to obtain fungi that do not contain selectable markers. This essence of this MARKER GENE FREE™ transformation technology is disclosed in EP-A-0 635 574, which is herein incorporated by reference. Of these selectable markers the use of dominant and bidirectional selectable markers such as acetamidase genes like the amdS genes of A. nidulans, A. niger and P. chrysogenum is most preferred. In addition to their bidirectionality these markers provide the advantage that they are dominant selectable markers that, the use of which does not require mutant (auxotrophic) strains, but which can be used directly in wild type strains.
Optional further elements that may be present in the nucleic acid constructs of the invention include, but are not limited to, one or more leader sequences, enhancers, integration factors, and/or reporter genes, intron sequences, centromers, telomers and/or matrix attachment (MAR) sequences. The nucleic acid constructs of the invention may further comprise a sequence for autonomous replication, such as an ARS sequence. Suitable episomal nucleic acid constructs may e.g. be based on the yeast 2μ or pKD1 (Fleer et al., 1991, Biotechnology 9: 968-975) plasmids. Alternatively the nucleic acid construct may comprise sequences for integration, preferably by homologous recombination (see e.g. WO98/46772). Such sequences may thus be sequences homologous to the target site for integration in the host cell's genome. The nucleic acid constructs of the invention can be provided in a manner known per se, which generally involves techniques such as restricting and linking nucleic acids/nucleic acid sequences, for which reference is made to the standard handbooks, such as Sambrook and Russel (2001) “Molecular Cloning: A Laboratory Manual (3rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, or F. Ausubel et al, eds., “Current protocols in molecular biology”, Green Publishing and Wiley Interscience, New York (1987).
In a further aspect the invention relates to fermentation processes in which the transformed host cells of the invention are used for the production of citric acid and products that can be derived from further metabolic routes from citric acid. Such a fermentation process may be an aerobic fermentation process, but since the location of the enzyme is outside the mitochondrion advantageously an oxygen-limited or anaerobic fermentation process may be applied. This enables a lot of possible circumstances or conditions under which production of the citric acid can still occur. In particular circumstances with an inactive TCA cycle which are normally believed to be incompatible with citric acid production. In particular various yeast species are able to grow anaerobically by fermentation. For pertaining a suitable cofactor balance in particular yeast strains able to use NO3 such as Dekkera bruxellensis and Pichia anomola are preferred. The fermentation process may either be a submerged or a solid state fermentation process.
In a solid state fermentation process (sometimes referred to as semi-solid state fermentation) the transformed host cells are fermenting on a solid medium that provides anchorage points for the fungus in the absence of any freely flowing substance. The amount of water in the solid medium can be any amount of water. For example, the solid medium could be almost dry, or it could be slushy. A person skilled in the art knows that the terms “solid state fermentation” and “semi-solid state fermentation” are interchangeable. A wide variety of solid state fermentation devices have previously been described (for review see, Larroche et al., “Special Transformation Processes Using Fungal Spores and Immobilized Cells”, Adv. Biochem. Eng. Biotech., (1997), Vol 55, pp. 179; Roussos et al., “Zymotis: A large Scale Solid State Fermenter”, Applied Biochemistry and Biotechnology, (1993), Vol. 42, pp. 37-52; Smits et al., “Solid-State Fermentation-A Mini Review, 1998), Agro-Food-Industry Hi-Tech, March/April, pp. 29-36). These devices fall within two categories, those categories being static systems and agitated systems. In static systems, the solid media is stationary throughout the fermentation process. Examples of static systems used for solid state fermentation include flasks, petri dishes, trays, fixed bed columns, and ovens. Agitated systems provide a means for mixing the solid media during the fermentation process. One example of an agitated system is a rotating drum (Larroche et al., supra). In a submerged fermentation process on the other hand, the transformed fungal host cells are fermenting while being submerged in a liquid medium, usually in a stirred tank fermenter as are well known in the art, although also other types of fermenters such as e.g. airlift-type fermenters may also be applied (see e.g. U.S. Pat. No. 6,746,862).
Preferred in the invention is a submerged fermentation process, which is performed in batch or fed-batch . This means that there is a continuous input of feed containing a carbon source and/or other relevant nutrients in order to improve citric acid yields. The input of the feed can, for example, be at a constant rate or when the concentration of a specific substrate or fermentation parameter falls below some set point.
There are also fermentation processes where a fungus grows on a solid support in an aqueous phase in so-called biofilm processes. In those conditions there will be an oxygen limitation meaning that the metabolism in such a case at least partially will be anaerobically. Biofilms have been used for a long time in water treatment facilities where they were called slime, mats or sludge, but no other practical use was seen until recently. This has brought that most of the available information is on bacterial and, in recent years, on yeast biofilms. Filamentous fungi are naturally adapted to growth on surfaces and in these conditions they show a particular physiological behaviour which it is different to that in a submerged culture; thus, they can be considered as biofilm forming organisms according to the above concept. Differential physiological behaviour of most attached fungi corresponds principally to a higher production and secretion of enzymes and also to a morphological differentiation which is absent in submerged cultures (Akao, T. et al.,Curr. Genet. 41:275-281, 2002; Biesebeke, R. et al., FEMS Yeast Res. 2:245-248, 2002). The advantages of this form of growth have been industrially exploited by two culture systems: SSF and cell immobilization (Gutierrez-Correa, M. and Villena, G., Rev. peru. Boil. 10(2):113-124, 2003). Once citric acid is produced in the host cell this citric acid can be used as a substrate for further metabolic processes. One of these metabolic processes is the production of itaconic acid. For this a conversion from citric acid via cis-aconitate to itaconic acid has to be performed via the enzymes aconitase and CAD (cis-aconitate decarboxylase). Such a conversion and further methods of additionally increasing the production of itaconic acid from cis-aconitate has been described in WO 2009/014437, WO 2009/104958 and WO 2009/110796.
Next to a pathway to itaconic acid, citric acid can also be used as a starting point for other metabolic routes. One of the most commercially interesting routes is the production of methacrylic acid. Methacrylic acid can be produced directly by decarboxylation of itaconic acid, but it can also be produced through other metabolic routes (see Carlsson, M. et al., Ind. Eng. Chem. Res. 33:1989-1996, 1994). Citric acid is also one of the basic building blocks in the biosynthesis of fatty acids and triglycerides. Fatty acids form important storage molecules for energy, which energy later can be used, e.g. when fatty acids have been used as a source of biodiesel. The exact nature of the fatty acid is—for use as biofuel—less relevant, since all types of plant fatty acids may be used as such. Fatty acids can, of course, also be used as such, e.g. as food additives. This is especially important in the case of the essential fatty acids, like linoleic acid and a-linolenic acid. for the production of other compounds, such as biodegradable plastics.
Further, citric acid can be used to be a starting point for the biosynthesis of lysine (via homocitrate and homo-cis-aconitate).
This pathway is also required for the biosynthetic production of aminoadipate which is an intermediate for penicillin and other antibiotic compounds. Lysine, in turn, may be used as a starting point for the production of caprolactam (see US 2009/005532, and from there be used for the production of plastics (such as nylon-6, a polyamide).
Further, citrate can also be used as a precursor for the mevalonate pathway (see
It has further been found that the cluster in which the citB gene is residing contains other genes that have a relation with the pathways in which citrate is involved. In the citB (An08g10920) cluster that is present in a particular A. niger strain the following genes can be found: An08g10860 (fatty acid synthase) An08g10870 (2-methylcitrate dehydratase (prpD)),); An08g10880 (GAL4; GAL4-like Zn2Cys6 binuclear), An08g10930 (3-oxoacyl-[acyl-carrier-protein] synthase, fatty acid synthase); An08g10970 (MFS multidrug transporter); An08g10980 (transcription factor acetate regulatory DNA binding protein facB). . (Over)expression of any of these genes, next to the expression of citB is thought to be especially favorable to increase the production and usurpation of intracellular citrate.
The table 2 below gives an overview of proteins/genes in Aspergillus niger and S. cerevisiae belonging to the enzyme classes citrate synthase, aconitase and cis-aconitase decarboxylase. For all members in A. niger the results of expression analysis is given by RNA sequencing results in the WT strain and an itaconic acid producing strain (transgenic for CAD by carrying extra gene copies of the cis-aconitate decarboxylase from A. terreus as described in WO 2009/014437). This shows that An08g10920, tentatively called citB, encoding a citrate synthase without a predicted mitochondrial localization, is highly induced in the itaconic acid production strain. This gene has no homologue in S. cerevisiae. Only in closely related black Aspergilli homologues are present (see below under genome mining citB gene cluster). Also one of the predicted cytosolic cis-aconitase decarboxylase (prpD) genes from A. niger, An08g10870 which is clustered with citB is highly induced. Also the canonical cytosolic aconitase An08g10530 more distantly linked is induced in the CAD strain.
In S. cerevisiae all three citrate synthase proteins and the single prpD gene are mitochondrial, while both aconitases are cytosolic as predicted for the common metabolic pathways.
An08g10920/ANI
—
1
—
1474074
citrate synthase citB
cyto: 10.0
9515
917
An08g10530/ANI
—
1
—
1410074
aconitase
cyto: 19.0
11203
5897
An05g02230/ANI
—
1
—
578044
aconitase
cyto: 12.5
234
89
An08g10870/ANI
—
1
—
2490074
prpD
cyto: 16.5
6099
570
From this Table it appears that two of the A. niger proteins are clearly located in the mitochondrion (An09g09980 and An15g01920), while two A. niger genes are located outside the mitochondrion (An01g09940 and An08g10920), while the location of one protein is undecided (An09g03570).
In a homology tree (see
RNAseq is a new transcriptomics platform which allows direct sequencing of mRNAs. This means that no arrays are required and all expressed RNA is measured (non-coding, non annotated). Shake flask cultures in fermentation medium described below were grown for 46 hours at 33° C. from which biomass samples were harvested. Total RNA was isolated from biomass samples using Trizol (Invitrogen). The total RNA was send to BaseClear (The Netherlands). Before random mRNA sequencing could be performed, mRNA purification was performed via oligo-dT beads (Illumina TruSeq RNA samp.prep), followed by first-strand cDNA synthesis with random primers. Adaptor ligation, adding 120 bp, was carried out, followed by ˜270 bp gel-isolation (cDNA inserts ˜150 bp). Subsequently, paired-end sequencing was performed, resulting in Illumina HiSeq data (28-29 M reads/sample). Data analysis was performed to obtain output files of RNA-Seq alignments (*.clc, *,sam) and RNA-Seq expression tables (*.csv, *.clc, *.xlsx). Sample-normalised expression values were expressed as RKPM/sample (=Reads per Kilobase of exon model per Million mapped reads (Mortazavi et. al 2008)). The data analysis performed at TNO comprised of defining the “Floor” of RPKM values (Excel) (S<1 was defined as S=1). After introducing the “Floor” the differentials of the expression values of the CAD transformant and wildtype were calculated in Excel (R=Sx/Sref; 2logR ratios). Below table 2 provides the RNAseq data (counts and 2logR ratios) of the genes directly surrounding the citrate synthase genes which might belong to the putative citrate synthase/prpD gene clusters. AB1.13 data refer to the WT A. niger host strain, while AB1.13CAD refer to the itaconic acid producing strain (CAD) carrying extra gene copies of the cis-aconitate decarboxylase from A. terreus as described in WO 2009/014437. Note that RNAseq values lower than 100-200 represent very low expression. Of the related genes/gene cxlusters only the citB cluster (An08g10860-An08g1011030, in bold and italics) shows significantly induced expression in the AB1.13CAD strain (Table 3) The other gene regions containing citrate synthase, aconitase and cis-aconitate decarboxylase genes (underlined) show no induction (Table 3).
ANI_1_1328014
−1.94
An01g09930
ANI
—
1
—
2948014
2-methylcitrate dehydratase (prpD)
−2.53
An01g09940
ANI
—
1
—
2950014
citrate synthase
−0.27
An01g09950
ANI
—
1
—
2952014
immune-responsive protein (prpD)
229
170
An01g10060
ANI
—
1
—
2962014
Zn(II)2Cys6 transcription factor
1565
1632
−0.10
An15g01780
ANI
—
1
—
306134
2-methylcitrate dehydratase (prpD)
144
An15g01810
ANI
—
1
—
1214134
C6 zinc finger domain protein
345
616
−0.87
An15g01920
ANI
—
1
—
1226134
citrate synthase
An09g03570
similarity to citrate synthase citA
318
−2.28
An09g06220
ANI
—
1
—
1536084
immune-responsive protein (prpD)
9051
8977
−0.02
An09g06680
ANI
—
1
—
876084
citrate synthase citA
A. niger strains were cultured under different fermentation conditions (see table 4). Five-Liter controlled batch fermentations were performed in New Brunswick Scientific Bioflow 3000 fermentors.
The following conditions were used unless stated otherwise:
Temp. 37° C.
pH start 3.5 set point 2.3
DO set points Day 1: 75%
Day 2,3,4: 50%
Subsequent days: 25%
All media were prepared in demineralized water.
For the shake flask cultures the fermentation medium described above was used. The cultures were grown for 46 hours at 33° C. from which biomass samples were harvested.
RNA was isolated from biomass samples using Trizol from Invitrogen. Equal amounts of RNA (8 micrograms) were loaded on a RNA gel and blotted on Hybond N+ membrane from GE Healthcare.
From the RNAseq data it was shown that several genes in a gene cluster, including the citB gene, were upregulated in the TNO-CAD strain compared to the TNO-WT strain.
To confirm the RNAseq results and to analyze different strains and different fermentation conditions, Northern analysis was carried out.
Primers were designed to amplify gene fragments by PCR of four upregulated genes from the gene cluster (citB, MFS, citR and prpD, seeTable 5) and other interesting genes (gpdA, citA, CAD). The labeling of the gene fragments was carried out using the PCR DIG Probe Synthesis Kit (Roche). Hybridization was performed using the DIG-High Prime DNA Labeling and Detection Starter Kit II (Roche).
The results of the Northern analysis of the fermentation samples are shown in the table 6 below.
From the Northern analysis it was concluded that the expression of the genes from the gene cluster showed low expression levels, or no expression was detected, or were below detection limits.
Northern analysis revealed very low expression levels, most likely below the detection limit of the method. Therefore, quantitative RT-PCR was carried out using the Superscript III platinum One Step Quantitative RT-PCR kit (Life Technologies) to analyze the expression of the citB gene (seeTable 6). A primer-probe combination for the citB gene was designed using the software Primer Express 2.0 (Applied Biosystems). To compare the expression level of citB with a highly expressed gene, also gpdA primers were designed. For the normalization of the citB and gpdA data, also a quantitative RT-PCR was carried out using 18S primers. The quantitative PCR was performed on the 7500 Fast Real time PCR system (Applied Biosystems). The total RNA isolated from biomass of fermentation experiments, which was used in the Northern analysis, was analyzed in this method. Also the total RNA used for the RNAseq experiment was analyzed and total RNA isolated from A. niger strains grown in a new shakeflask culture experiment was analyzed. In the normalized RT-qPCR results can been seen that the citB gene is induced in certain conditions. For the samples used for RNAseq RT-qPCR confirmed the RNAseq results.
In table 7 the results of a genome mining effort of the citB gene cluster is given.
Sequences were obtained from NCBI. Alignments were performed using BLASTX with a BLOSUM62 matrix and the default settings for BLASTX (http://www.ncbi.nlm.nih.gov/blast/b12seq/wblast2.cgi).
Aspergillus kawachii
Penicillium marneffei
Talaromyces stipitatus
Aspergillus flavus
Aspergillus oryzae
Aspergillus kawachii
Aspergillus flavus
Aspergillus oryzae
Aspergillus kawachii
Aspergillus fumigatus
Neosartorya fischeri
Aspergillus clavatus
Aspergillus terreus
Zea mays
Aspergillus kawachii
Aspergillus flavus
Aspergillus oryzae
Penicillium marneffei
Aspergillus kawachii
Aspergillus oryzae
Aspergillus flavus
Glomerella graminicola
Tuber melanosporum
Aspergillus kawachii
Trichoderma virens
Trichoderma reesei
Trichoderma atroviride
Aspergillus flavus
Aspergillus oryzae
Aspergillus kawachii
Aspergillus oryzae
Aspergillus flavus
Aspergillus kawachii
Exophiala dermatitidis
Talaromyces stipitatus
Penicillium marneffei
It appears that the genes as depicted in NP_001142237.1, GAA88109.1, XP_002384448.1, XP_001827205.1 and XP_002148678.1 can be considered to be orthologs of the Aspergillus niger citrate synthase.
Using the search tool Sybil on the AspGD website (Broad Institute) (http://aspgd.broadinstitute.org/cgi-bin/asp2_v3/shared/show_protein_cluster.cgi?site=asp2_v8) orthologous clusters from multiple genomes can be depicted as shown in
The citrate synthase gene (An08g10920) was further used to search for the ortholog clusters in other Aspergillus genomes. As can be seen in
To establish the overexpression of the citB gene in A. niger, a PCR generated copy of the gene was generated. For this purpose two sets of primers were generated as shown below. PCR amplification based on A.niger genomic DNA resulted in the isolation of PCR fragments from which the complete coding region of the citB gene could be isolated as a BsmBI-NcoI fragment.
AAAGCGAGAGTGGTACC-5′
AAAGCGAGAT-5′
The resulting BsmBI-NcoI fragment was cloned in the NcoI site of the Aspergillus expression vector pABgpd-I (
Subsequently, an itaconic acid producing Aspergillus niger strain (Li, A. et al., Appl. Microbial. Biotechnol. 1-11, 2013; Li, A. et al. Fungal Genet. Biol. 48:602-611, 2011) was transformed with the citB overexpression vector. PyrG+ transformants were purified by single colony purification and retested for their PyrG+ phenotype. Several PyrG+ transformants were subsequently cultured in shake flask cultures from which the expression of the introduced citB expression cassette was analyzed using quantitative RT-PCR. In addition Southern analysis was carried out to confirm the presence of intact copies of the expression cassette in the transformants.
The transformants with the highest copy number and/or highest citB expression level were cultured in batch fermentations. Following up, the media samples were analyzed by HPLC for the amount of itaconic acid produced by the A. niger transformants. Besides this, other organic acids like citric acid and oxalic acid were also analyzed due to their relevance in the assumed itaconate production pathway in Aspergillus niger.
For the screening and selection of A. niger transformants, our previously developed screening assay was used (Li et al. 2012). After seeding, all plates were directly sealed with an oxygen permeable film (Sealing film sterile, breathable M20193, Dispolab the Netherlands), placed in a plastic air bag and cultivated in a 33 ° C., 850 rpm incubator (Microtron, Infos-ht) forfor 60 h,. In the end of the cultivation, culture medium was harvested and used for HPLC analysis.
For shakeflask and controlled batch fermentations, the production medium
(M12) described in our previous study (Li et al. 2012) with the following composition was used (per liter): 100 g glucose, 2.36 g (NH4)2SO4, 0.11 g KH2PO4, 0.5 g MgSO4.7H2O, 0.6 mg FeSO4.7H2O, 2.5 mg CuSO4.5H2O, 0.6 mg ZnSO4.7H2O, 0.074 g NaCl, and 0.13 g CaCl2.2H2O. This medium was prepared in demineralised water. The production medium M12+Cu has an extra addition of 2.5 mg CuSO4.5H2O (0.01 mM). For controlled fermentation pre-cultures were prepared by inoculation of 106 spores per milliliter in 2×100-mL production medium in two 500 mL baffled Erlenmeyer flasks. After 64 h at 33° C. and shaking at 125 rpm, the pre-cultures were used for inoculation of the fermenters. Fermentations were performed in 5-L Benchtop Fermentors (BioFlo 3000, New Brunswick Scientific Co., Inc.) at 33° C. The basic pH regime was initiated at 3.5 and subsequently regulated at 2.3, by addition of 4 M KOH (base). Struktol was applied as antifoam agent (Schill & Seilacher) in all cultures throughout the fermentation. Air was used for sparging the bioreactor at a constant flow of 0.25 vvm [(vol.liquid)−1 min−1]. The solubility of oxygen in the medium is around 225 μMol at 33 ° C. Pure air sparging was calibrated as 100% D.O., whereas pure nitrogen sparging was calibrated as 0% D.O. In the basic D.O. regime, D.O. was set at 100% from the start of the fermentation. As soon as due to mycelial growth D.O. levels dropped below 25%, stirrer agitation was increased automatically to maintain D.O. at 25%. For studying the influence of oxygen availability on itaconic acid production, D.O was fixed throughout the whole fermentation at 10, 15, 20, and 25% for strain N201 CAD and at 5, 10, and 20% for strain HBD 2.5. The different percentage of D.O. was obtained by varying the mixture of air/nitrogen in the inlet gas.
The cultured transformants were analysed for the presence of citric acid and derivatives in microplate cultures. Based on these cultures several transformants producing increased itaconic acid levels were selected for further research.
Based on the results obtained in microplate screening a selection of transformants was grown in shakeflask cultures as described by Li et al., 2012, 2013 and analysed for itaconic acid productivity and yield
As shown the introduction of the citB gene into an A. niger strain already expressing cadA resulted in increased productivity and yields of secreted itaconic acid.
Introduction of two previously identified organic acid transporters (MTT/MFS;) as described in WO 2009/104958 and WO 2009/110796 in a single host strain also resulted in increased productivity of itaconic acid.
In a strain already simultaneously expressing the A.terreus cadA, mfsA and mttA genes, which genes and strains have been described in WO 2009/014437, WO 2009/104958 and WO 2009/110796 as shown in the table in Example 7A, above, (strains CADMFSMTT#63 or #49), the A. niger citB expression vector was introduced by cotransformation using the phleomycin resistence marker for transformant selection. From the resulting tranosformants strain CitB #99 was selected for further analysis
Controlled batch cultivations were performed in 5 liter batch fermentors (BioFlo 3000, New Brunswick Scientific Co., Inc.). The production medium, as published earlier by An Li et al., 2012, consists of the following (per litre): 100 g glucose, 2.36 g (NH4)2SO4, 0.11 g KH2PO4, 0.5 g MgSO4.7H2O, 0.6 g FeSO4.7H2O, 2.5 mg CuSO4.5H2O, 0.6 mg ZnSO4.7H2O, 0.074 g NaCl and 0.13 g CaCl2.2H2O. This medium was prepared in demineralized water. Inoculum was prepared with 1.0-106 spores/mL in 100 mL production medium in 500 mL baffled Erlenmeyer flasks. Inoculum was then incubated at 33° C. for 72 hours and shaking at 125 rpm. Temperature was kept stable at 33° C. throughout the fermentation. The fermentation starts with a pH of 3.5 and afterwards is kept stable at 2.3 by addition of 4M KOH. The bioreactor was sparged with a constant flow of 1.25 vvm [(vol.liquid)−1 min−1] air. The system was calibrated as 100% D.O. by sparging the bioreactor with pure air whereas pure nitrogen sparging was calibrated as 0% D.O. Throughout the course of the fermentation the D.O. was kept at 20%, which is achieved by applying various mixtures of air and nitrogen in the inlet gas. Struktol (Schill & Seilacher) was used as antifoaming agent. Autosamples were taken every six hours using a 0.22 μM filter (Applikon Biotechnology, USA).
Filter-sterilized fermentation samples were analyzed by high-performance liquid chromatography (HPLC) to quantify metabolites and assess organic acid production. Samples were loaded on a WATERS e2695 Separations Module outfitted with an Aminex HPX-87H column (Bio-Rad) and 5 mM H2SO4 as eluent. Metabolites were detected by a refractive index detector (WATERS 2414) and a dual-wavelength detector (WATERS UV/Vis 2489) simultaneously. Empower Pro was used as software for the processing of data (Empower 2 Software, copyright 2005-2008, Waters Corporation, Milford, Mass., USA).
In order to compare the organic acid production capacity of the CitB #99 strain with the AB1.13 CAD+MTT+MFS strain, controlled batch fermentations were performed. The glucose consumption and organic acid production capacity of the two strains is depicted in
Shakeflask cultures
Cultivations in shakeflasks were performed in order to assess if the CitB #99 strain can grow on second generation feedstocks e.g. glycerol. For this experiment crude waste glycerol was acquired fro a biodiesel production plant. In the biodiesel process a waste product containing glycerol as mayor carbon source is produced as waste product. The experiment was performed in 500 mL baffled Erlenmeyer shakeflasks with a volume of 100 mL. Medium was prepared by adding 10 mL of crude glycerol from the company to 90 mL demineralized water. Preculture was prepared by inoculating 1.0-106 spores/mL in 100 mL production medium in 500 mL baffled Erlenmeyer flasks and grown overnight at 33° C. and shaking at 125 rpm. From this preculture 2 mL was used as inoculum.
In order to assess if the CitB #99 strain can grow on second-generation feedstock, shakeflask cultivations were performed with glycerol as C-source (
For the overexpression of A. niger citB and A. terreus cadA in Saccharomyces cerevisiae an expression vector was synthesized at Geneart (Life technologies Europe, Bleiswijk, The Netherlands) containing two expression cassettes. The Saccharomyces codon optimized gene encoding the A. niger CitB protein was inserted between the gpd promotor and CYC1 terminator of Saccharomyces. The Saccharomyces codon optimized gene encoding the A. terreus CAD protein was inserted between the tef promotor and ADH1 terminator of Saccharomyces. In between both expression cassettes the URA3 marker was placed in antisense. The complete fragment was surrounded with URA3 flanking regions for integration at the URA3 locus in Saccaromyces cerevisiae.
GCGGCCGCGATAAGTTTTGACCATCAAAGAAGGTTAATGTGGCTGTGGTTTCAGGGTCCA
TAAAGCTTT
CAGTTTATCATTATCAATACTCGCCATTTCAAAGAATACGTAAATAATTAA
TAGTAGTGATTTTCCTAACTTTATTTAGTCAAAAAATTAGCCTTTTAATTCTGCTGTAAC
CCGTACATGCCCAAAATAGGGGGCGGGTTACACAGAATATATAACATCGTAGGTGTCTGG
GTGAACAGTTTATTCCTGGCATCCACTAAATATAATGGAGCCCGCTTTTTAAGCTGGCAT
CCAGAAAAAAAAAGAATCCCAGCACCAAAATATTGTTTTCTTCACCAACCATCAGTTCAT
AGGTCCATTCTCTTAGCGCAACTACAGAGAACAGGGGCACAAACAGGCAAAAAACGGGCA
CAACCTCAATGGAGTGATGCAACCTGCCTGGAGTAAATGATGACACAAGGCAATTGACCC
ACGCATGTATCTATCTCATTTTCTTACACCTTCTATTACCTTCTGCTCTCTCTGATTTGG
AAAAAGCTGAAAAAAAAGGTTGAAACCAGTTCCCTGAAATTATTCCCCTACTTGACTAAT
AAGTATATAAAGACGGTAGGTATTGATTGTAATTCTGTAAATCTATTTCTTAAACTTCTT
AAATTCTACTTTTATAGTTAGTCTTTTTTTTAGTTTTAAAACACCAGAACTTAGTTTCGA
CGGATTCTAGA
ATGCCAGATATTGCTTCTAATGGTGCTAGAAATGGTGCTTCTCAAAACG
CCCATAAGGTTGTTTGTGACGGCGTCGTACAAGAGAACGTGGGAACTTTTTAGGCTCACC
AAAAAAGAAAGAAAAAATACGAGTTGCTGACAGAAGCCTCAAGAAAAAAAAAATTCTTCT
TCGACTATGCTGGAGGCAGAGATGATCGAGCCGGTAGTTAACTATATATAGCTAAATTGG
TTCCATCACCTTCTTTTCTGGTGTCGCTCCTTCTAGTGCTATTTCTGGCTTTTCCTATTT
TTTTTTTTCCATTTTTCTTTCTCTCTTTCTAATATATAAATTCTCTTGCATTTTCTATTT
TTCTCTCTATCTATTCTACTTGTTTATTCCCTTCAAGGTTTTTTTTTAAGGAGTACTTGT
TTTTAGAATATACGGTCAACGAACTATAATTAACTAAACTCTAGAATGACCAAGCAATCC
TATAAAAAGGAACTATCCAATACCTCGCCAGAACCAAGTAACAGTATTTT
GCGGCCGC
The citB expression fragment was isolated from the synthesized vector using BamHI-SstI and cloned into the pFL61 yeast expression vector (ATCC77215; http://www.lgcstandards-atcc.org/Products/All/77215.aspx; Minet M. et al. Complementation of Sacchammyces cerevisiae auxotrophic mutants by Arabidopsis cDNA. Plant J. 2: 417-422, 1992.), which was digested with BamHI and SstI. The cadA expression fragment was isolated using Acc65I-EcoRI and cloned into the pFL61 yeast expression vector. The resulting citB and cadA expression vectors were transformed to the Saccharomyces cerevisiae strain CEN.PK113-5D using the electroporation protocol as described in (Transformation of commercial baker's yeast strains by electroporation., Gysler et al. , Biotechnology Techniques Vol 4 No 4 285-290 (1990)) The yeast transformants were purified by single colony purification and analyzed with PCR for the presence of the expression vector.
Subsequently, the transformants carrying citB or cadA genecopies were cultured in microtitreplate cultures under aerobic and anaerobic conditions and analyzed for the organic acid production using HPLC.In cadA expressing strains under both anaerobic and aerobic conditions itaconic acid production was detected in the culture medium.
| Number | Date | Country | Kind |
|---|---|---|---|
| 13166305.6 | May 2013 | EP | regional |
This Application is a divisional of application Ser. No. 14/888,410, having an international filing date of 2 May 2014, now allowed, which is national phase of PCT application PCT/NL2014/050284 having an international filing date of 2 May 2014, which claims benefit of European patent application No. 13166305.6 filed 2 May 2013. The contents of the above patent applications are incorporated by reference herein in their entirety.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14888410 | Oct 2015 | US |
| Child | 15849465 | US |
